First-in-Class Oral Semaglutide Overcoming Barriers of Incretinisation in the Indian Context
patients from other parts of the world. However, subcutaneous treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is limited by their injectable mode of administration. The present review highlights barriers...
Relevance: The present review highlights barriers to incretinisation with GLP-1RAs and the role of first-in-class oral semaglutide in the Indian context and provides guidance to physicians on its initiation and uses.
Share
Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom - Advances in Therapy
Source : https://link.springer.com/article/10.1007/s12325-022-02423-8
Objectives The objective of the current preliminary study was to present the cost-effectiveness analyses submitted to the National Institute for Health and Care Excellence (NICE) (TA10765) that deemed semaglutide 2.4...
Conclusion: Semaglutide 2.4 mg s.c. injection is a cost-effective therapy compared to D&E alone for patients with obesity and weight-related comorbidities in the UK. Sensitivity and scenario analyses confirm the robustness of the analyses.
Share
Metformin and Cervical Cancer Risk in Patients with Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36604960/
Metformin use in patients with newly diagnosed diabetes was associated with a lower risk of cervical cancer in Korea. Furthermore, a significant association was found between the use of metformin...
Conclusion: Metformin use in patients with newly diagnosed diabetes was associated with a lower risk of cervical cancer in Korea. Furthermore, a significant association was found between the use of metformin and cervical cancer in a dose- and duration-dependent manner and among those over 50 years old.
Share
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
Source : https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2007-2061
CC BY-NC-ND 4.0 · Exp Clin Endocrinol Diabetes DOI: 10.1055/a-2007-2061 1 Innere Medizin - Diabetologie und Endokrinologie, Gemeinschaftskrankenhaus Bonn, Bonn, Germany 4 Novo Nordisk Pharma GmbH, Mainz, Germany...
Conclusions: In a real-world population in Germany, patients with type 2 diabetes treated with once-weekly semaglutide experienced clinically significant improvements in glycaemic control and body weight. These results support use of once-weekly semaglutide in routine clinical practice in adult patients with type 2 diabetes in Germany.
Share
Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations
Intensive lifestyle intervention (ILI) that includes counseling on behavioral, physical activity, and dietary strategies is the first-line treatment for obesity. In clinical research trials, ILI produces losses of 7-8% of...
Conclusions/Relevance: In this paper, we discuss considerations for the selection of individuals who are candidates for semaglutide and special considerations related to the use of this medication. These include its efficacy and safety, as well as its contraindications, potential adverse effects, management of comorbidities and drug...
Share